Multiple Sclerosis B-Cell Repertoires Shift After DMD Treatment

A 2026 Journal of Neuroinflammation study involving 33 people with multiple sclerosis and 10 healthy controls found disease-specific B-cell repertoire signatures even when ordinary B-cell subset counts looked modest, then showed that most disease-modifying therapies shifted repertoire diversity after 6 months.

B cells are immune cells that can become antibody-producing cells, present antigens to T cells, and help maintain inflammatory loops. In multiple sclerosis (MS), B-cell biology is already clinically important because CD20-targeting drugs such as ocrelizumab, ofatumumab, and ublituximab reduce inflammatory disease activity.

Immunoglobulin repertoire sequencing asks a more specific question than a cell count: which antibody-gene rearrangements are present, how expanded the clones are, and whether certain gene families are overused. A normal blood count can say how many B cells are present; repertoire sequencing can show whether the B-cell pool looks clonally narrowed, antigen-experienced, or therapy-remodeled.

Untreated MS Showed Lower Double-Negative B-Cell Diversity

Vasilenko et al. sorted 4 peripheral B-cell subsets from blood: naive B cells, memory B cells, double-negative B cells, and plasmablasts. Double-negative B cells lack the usual IgD and CD27 markers used to classify naive and memory cells; in autoimmune disease, they can behave like antigen-experienced cells that may have escaped ordinary regulatory checkpoints.

In the main healthy-control comparison, the researchers compared 18 treatment-naive MS patients with 10 healthy controls after removing fingolimod and natalizumab datasets from that cross-sectional analysis because of library-generation differences. The ordinary subset percentages did not show a dramatic MS-vs.-control separation. Repertoire structure did.

• Double-negative B cells: clonal diversity was significantly lower in untreated MS, consistent with more pronounced clonal expansion in that subset.
• Somatic hypermutation: double-negative B cells showed significantly higher somatic hypermutation in MS, while memory B cells showed less.
• IGHV gene use: untreated MS showed higher IGHV2 use in naive B cells, lower IGHV2 use in double-negative B cells, and a plasmablast pattern with lower IGHV2, higher IGHV3, and a trend toward lower IGHV5.

Somatic hypermutation means mutation introduced into antibody genes after B cells encounter antigen, a normal way the immune system improves antibody binding. In this setting, more mutation and lower diversity in double-negative cells point toward a more selected, antigen-experienced compartment rather than a randomly mixed B-cell pool.

Disease-Modifying Therapies Shifted the Repertoire Toward Fewer Memory Clones

The longitudinal part followed all 33 MS patients from baseline to 6 months after starting ozanimod, fingolimod, dimethyl fumarate, teriflunomide, cladribine, or natalizumab. The key pattern was not identical across drugs, but most non-natalizumab therapies pushed the peripheral repertoire away from the untreated memory-B-cell-heavy pattern.

Ozanimod had the clearest within-patient signal. After 6 months, clonal diversity decreased in naive B cells, memory B cells, and plasmablasts, while clones with more than 50 members increased in memory B cells and plasmablasts. The researchers interpreted this as activation within the naive pool plus reduction of overall clone number in antigen-experienced compartments.

Other therapies showed similar direction but weaker statistical support because groups were small. Fingolimod, dimethyl fumarate, teriflunomide, and cladribine generally moved memory B-cell diversity downward or showed matching trends. Natalizumab was the exception: it can increase circulating memory B-cell fractions by blocking alpha-4 integrin-mediated trafficking, so its peripheral blood pattern need not match lymphocyte-retention or depletion therapies.

Disease-modifying therapies are MS treatments intended to reduce inflammatory activity and future damage beyond symptom relief. The repertoire result gives those drugs a shared immune-remodeling interpretation: even drugs with different mechanisms may converge on antigen-experienced B-cell pools, especially memory B cells.

Peripheral B-Cell Findings Fit Earlier MS Repertoire Work

Kemmerer et al. had already shown that MS therapies differ in how they reshape peripheral B-cell subsets, including memory B-cell reductions under several treatments. Vasilenko et al. added a clone-level layer: broad subset counts and clone-level diversity answer different questions about how expanded the antibody-gene repertoires are inside those subsets.

Perez-Saldivar et al. later compared B-cell receptor repertoires during MS relapse and remission and reported reduced diversity plus more expanded clones in MS, especially during relapse. That makes the 2026 double-negative B-cell result less isolated: independent repertoire work also points toward clonal narrowing as part of active MS immune biology.

Cladribine-specific work by Ruschil et al. fits the treatment side of the story. Cladribine affected peripheral memory B-cell clones and clonal expansion, which matches the 2026 paper’s broader claim that therapy effects often run through antigen-experienced B-cell compartments rather than only through total B-cell counts.

EBV-Related Antibody Signals Changed, but Proteome Composition Stayed Stable

Epstein-Barr virus (EBV) is relevant because prior epidemiology and mechanistic work have tied EBV infection to MS risk, and Lanz et al. reported that clonally expanded MS B cells can bind EBNA1, an EBV nuclear antigen, and GlialCAM, a central nervous system protein. That finding helped support a molecular-mimicry hypothesis in which antiviral immunity may cross-recognize nervous-system targets.

Vasilenko et al. measured serum IgG antibodies against EBNA1 peptides and potential mimicry targets including GlialCAM, CRYAB, and ANO2. After ozanimod, antibody titers against EBNA1 p72, CRYAB, and ANO2 decreased significantly, with trends toward lower GlialCAM and EBNA1 AA393-412 titers. Teriflunomide significantly lowered EBNA1 p72 titers and showed a trend for lower EBNA1 AA425-444 titers. Dimethyl fumarate did not show significant titer changes.

The proteome result was more cautious. Immunoglobulin proteome analysis tries to connect antibody peptides in serum with the antibody transcripts found in B-cell sequencing. Across ozanimod, dimethyl fumarate, and teriflunomide, the qualitative peptide composition stayed broadly stable over 6 months, even though some quantitative antibody and transcriptome-alignment signals moved.

• Biological implication: therapies may suppress some antibody-output signals without immediately replacing the whole detectable serum antibody repertoire.
• Translation caveat: long-lived plasma cells in bone marrow contribute heavily to serum antibodies, so peripheral blood B-cell transcripts can only approximate what appears in serum.
• EBV caveat: antibody-titer movement does not prove that EBV mimicry drives a given patient’s disease activity.

Clinical Translation Is Biomarker Research, Not Treatment Selection

Evidence-strength note: this was a detailed mechanistic cohort study, not a clinical decision-rule study. It can support a research claim about peripheral immune architecture in MS. It cannot tell a patient which MS drug to choose, confirm relapse, or diagnose MS from a repertoire profile.

Several design limits keep the result in that lane. Treatment groups were small. Some statistical trends did not survive correction. EDSS disability correlations with VH germline usage were present in some analyses but disappeared after multiple-testing correction. Repertoire reconstruction can also create bias because sequencing depth, amplification, and clone-definition rules influence which clones appear expanded.

The stronger near-term use is mechanistic stratification. A future trial could ask whether patients whose memory B-cell clones remodel strongly after treatment have fewer new lesions, fewer relapses, or slower disability progression than patients whose repertoire stays antigen-experienced and clonally narrow. That would turn an immune-map signal into a treatment-monitoring question.

A monitoring test would also need sampling discipline. Repertoire metrics can move with infection, vaccination, steroid exposure, relapse timing, sequencing depth, and treatment start date, so a clinically useful panel would need predefined windows and reproducibility checks across laboratories.

This is especially important in MS, where treatment decisions already depend on relapses, MRI lesions, safety risk, pregnancy plans, and patient preference.

Questions About B-Cell Repertoires in Multiple Sclerosis

Does this mean B-cell repertoire testing can diagnose MS?

No. The study found disease-specific repertoire signatures in a small research cohort. Diagnosis still depends on clinical attacks, MRI dissemination in time and space, cerebrospinal fluid findings, and exclusion of better explanations.

Why focus on memory B cells?

Memory B cells are antigen-experienced cells that can present antigens, persist across immune responses, and help reactivate inflammatory circuits. Many MS therapies reduce or remodel memory B-cell compartments, which is why the treatment signal is biologically plausible.

Why was natalizumab different?

Natalizumab blocks immune-cell trafficking across barriers by targeting alpha-4 integrin. That can raise circulating memory B-cell fractions because cells are held in peripheral blood rather than entering tissues, so blood repertoire changes under natalizumab can move differently from depletion or lymphocyte-retention drugs.

What would make this clinically useful?

A stronger clinical case would require prospective sampling, external validation, MRI and relapse synchronization, and proof that repertoire changes predict outcomes beyond standard disease activity markers. Without that, the result is immune-biology mapping, not a treatment algorithm.

Related Posts:

• REDDI MEG Classifier Separated 4 Neurodegenerative Diseases at 0.81
• Multiple Sclerosis Iron MRI Linked to Cognitive Impairment in 12 Studies
• Multiple Sclerosis Frailty Exercise Improved Fatigue in 6 Weeks
• Serum MOG Blood Biomarker Rose During Multiple Sclerosis Relapse
• sCD27 Biomarker Flags Autoimmune Disease in Severe Psychiatric Disorders